Fulcrum therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined diseases. Inspired by patients, Fulcrum drug discovery begins with a deep exploration of disease biology in patient tissue samples. Fulcrum’s proprietary annotated compound library enables them to systematically approach drug discovery in genetically defined diseases. Drug targets are identified that modify gene expression and analyzed computationally using their proprietary database, FulcrumSeek.
Fulcrum’s lead program, losmapimod, is being investigated in clinical trials to beat facioscapulohumeral muscular dystrophy.